المؤلفون: Erna Kristin, Dwi Endarti, Levina Khoe, Woro Pratiwi, Rizaldy Pinzon, Ratih Febrinasari, Alfi Yasmina, Dwi Aris Agung Nugrahaningsih, Kartika Taroeno-Hariadi, Ramadhan Karsono, I Wayan Sudarsa, Muhammad Prenggono, Eva Herlinawaty, Kalsum Komaryani, Budi Hidayat, Mardiati Nadjib

المصدر: Asian Pacific Journal of Cancer Prevention. 23:2441-2447

مصطلحات موضوعية: Indonesia, Receptor, ErbB-2, Cost-Benefit Analysis, Antineoplastic Combined Chemotherapy Protocols, Humans, Breast Neoplasms, Female, Quality-Adjusted Life Years, General Medicine, Trastuzumab, Markov Chains

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bd5e77f3c1c86052a3af99de443d341
https://doi.org/10.31557/apjcp.2022.23.7.2441